{"id":"W2399066128","doi":"10.1158/1538-7445.sabcs15-p4-13-14","title":"Abstract P4-13-14: Time on treatment of everolimus, fulvestrant, and capecitabine for the treatment of HR+/HER2- metastatic breast cancer: A retrospective claims study in the US","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Capecitabine; Discontinuation; Fulvestrant; Everolimus; Internal medicine; Metastatic breast cancer; Regimen; Oncology; Aromatase inhibitor; Cancer; Hazard ratio; Tolerability; Breast cancer; Anastrozole; Aromatase; Adverse effect; Tamoxifen; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005655457,0.0002892784,0.0006976743,0.0001973509,0.0001328054,0.00001446344,0.0002043273,0.00004934951,0.0003309696],"category_scores_gemma":[0.00003129171,0.000120742,0.0001359086,0.0004173517,0.0005476474,0.00007895393,0.00001671703,0.0001335813,0.000004474236],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001756417,"about_ca_system_score_gemma":0.0004249929,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007462945,"about_ca_topic_score_gemma":0.00413925,"domain_scores_codex":[0.9976305,0.000190139,0.0004035492,0.0004827006,0.000761807,0.0005313302],"domain_scores_gemma":[0.9975001,0.001202,0.000150033,0.0006601515,0.0003845927,0.0001031022],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.03029096,0.01105955,0.1817295,0.0002977686,0.003275285,0.0001111327,0.02266437,0.0001687297,0.07572103,0.0001321259,0.0001575703,0.6743919],"study_design_scores_gemma":[0.01841664,0.01334254,0.9526576,0.0003871793,0.0002978975,0.0000294136,0.002013379,0.00002113378,0.01061657,0.0004242888,0.001639142,0.0001541581],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9840651,0.005530533,0.00001195812,0.004842279,0.00006142753,0.004493752,0.000918534,0.00001185286,0.00006456495],"genre_scores_gemma":[0.9895163,0.006521015,0.00003483544,0.00003335616,0.0002140598,0.003059507,0.000004292651,0.00004432877,0.0005722622],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7709281,"threshold_uncertainty_score":0.9991465,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07351609551178608,"score_gpt":0.4190183709053069,"score_spread":0.3455022753935208,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}